PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Contract manufacturer Pfizer CentreOne adds highly potent solid oral dose to its service portfolio

Second service addition by CMO this year
Pfizer CentreOne, a global contract manufacturing organization (CMO) embedded within Pfizer, recently announced that it has grown its service portfolio to include contract manufacturing of highly potent solid oral dose medicines. The service will be provided at the Pfizer Newbridge, Ireland, facility, which is now part of Pfizer CentreOne’s contract manufacturing network. The Pfizer site, near Dublin, has a long history of contract manufacturing and packaging highly potent solid oral drugs with advanced technologies.
“We are pleased to add the Newbridge facility to our network to offer a wider array of services and state-of-the-art containment, manufacturing and packaging technologies to our partners around the globe,” said Peter Stevenson, Vice President and General Manager, Pfizer CentreOne
Currently approved to supply pharmaceuticals in more than 100 markets, the site’s regulatory approvals include the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Agência Nacional de Vigilância Sanitária (ANVISA) (Brazil) and Pharmaceuticals and Medical Devices Agency (PDMA) (Japan).
Services
The Newbridge site manufactures high-potency non-cytotoxic solid oral dosage forms for human use. In addition to conventional manufacturing processes, the local team has deep experience with compounds that require complex processes, such as modification of powder and particle properties to create novel drug formulations, or those with enhanced solubility and dissolution properties.
Pfizer CentreOne manufactures the following compound types:

  • Highly active compounds
  • Hormones
  • Immunosuppressants
  • Sensitizers
  • Controlled drugs

Containment technologies span Occupational Exposure Band (OEB) 1-5 (Occupational Exposure Limit down to 0.01 µg/m3). Specialized technologies include active coating, low-dosage formulations and modified/extended release. For more information on Pfizer CentreOne’s highly potent solid oral dose capabilities, visit www.pfizercentreone.com/highly-potent-solids.
“Our team knows high-potency drugs inside and out, and we look forward to working with companies seeking a devoted contract manufacturing partner,” said John Sourke, Pfizer Newbridge site lead.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026